Core Viewpoint - Alkermes is positioning itself for growth in 2026 following a strong performance in 2025, with a focus on expanding its commercial platform and advancing its orexin pipeline, particularly through the recent acquisition of Avadel and the development of alixorexton [5][21]. Financial Performance - For 2025, Alkermes reported GAAP net income of $241.7 million and adjusted EBITDA of $394.0 million, ending the year with $1.3 billion in cash and total investments [2]. - Total revenues for 2025 were nearly $1.5 billion, driven by proprietary product net sales of approximately $1.2 billion, which grew 9% year over year [4]. Revenue Guidance for 2026 - Alkermes guided total revenues for 2026 between $1.73 billion and $1.84 billion, with proprietary product net sales expected to be between $1.52 billion and $1.60 billion [1]. - Manufacturing and royalty revenues are projected to be between $210 million and $240 million, reflecting the expiration of certain XEPLION royalties [1]. Expense Management - Cost of goods sold for 2026 is expected to be between $365 million and $385 million, influenced by purchase price accounting for LUMRYZ inventory [6]. - R&D expenses are projected to be between $445 million and $485 million, while SG&A expenses are expected to be between $890 million and $930 million, including one-time transaction costs related to the Avadel acquisition [7]. Product Performance - VIVITROL net sales for 2025 were $467.9 million, with a guidance of $460 million to $480 million for 2026 [10]. - ARISTADA net sales were $370.0 million in 2025, with a guidance of $365 million to $385 million for 2026 [11]. - LYBALVI saw a 24% increase in net sales to $346.7 million in 2025, with a guidance of $380 million to $400 million for 2026 [12]. - LUMRYZ generated approximately $279 million in net sales in 2025, with a guidance of $350 million to $370 million for 2026 [13]. Pipeline Developments - Alixorexton is expected to enter phase III trials in narcolepsy, with a detailed program planned [15][16]. - The company is also advancing two additional orexin 2 receptor agonists in phase I studies, with plans for further development in ADHD and fatigue associated with multiple sclerosis and Parkinson's disease [18]. Leadership Transition - A leadership transition is underway, with CEO Richard Pops set to step down and COO Blair Jackson taking over, while Pops will remain as chairman [21].